Glenmark Pharmaceuticals launches Bumetanide Injection Key Points:
- Glenmark Pharmaceuticals Inc., USA has introduced Bumetanide Injection USP as a generic alternative to Bumex® Injection, 0.25 mg/mL.
- The product is available in 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL (0.25 mg/mL) multi-dose vials.
- Glenmark’s Senior Vice President of Business Development Portfolio, Product Launch & Strategy, Vijay Raghavan, said that the company is excited to offer a more affordable option to Bumex® Injection, 0.25 mg/mL with the introduction of Bumetanide Injection USP and the launch of both single-dose and multi-dose vials serves the institutional business market.
- IQVIATM’s sales data for the year ending November 2022 showed that the Bumex® Injection, 0.25 mg/mL market generated annual revenue of around $16.5 million.
- Glenmark has a portfolio of 179 products that have been approved for sale in the U.S. market, and 46 additional ANDA’s are awaiting approval from the U.S. FDA.
- Glenmark is actively seeking external partnerships to expand and accelerate the growth of its pipeline and portfolio.
Glenmark Pharmaceuticals Inc., USA has introduced Bumetanide Injection USP in 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL (0.25 mg/mL) multi-dose vials, as a generic alternative to Bumex® Injection, 0.25 mg/mL, by Validus Pharmaceuticals LLC.
Vijay Raghavan, Senior Vice President of Business Development Portfolio, Product Launch & Strategy, commented on the launch, saying “We are thrilled to offer a more affordable option to Bumex® Injection, 0.25 mg/mL with the introduction of Bumetanide Injection USP. This launch of both single-dose and multi-dose vials exemplifies our dedication to serving the institutional business market.”
IQVIATM’s sales data for the year ending November 2022 showed that the Bumex® Injection, 0.25 mg/mL market generated annual revenue of around $16.5 million.
As of now, Glenmark has a portfolio of 179 products that have been approved for sale in the U.S. market, and 46 additional ANDA’s are awaiting approval from the U.S. FDA. In addition to these internal filings, Glenmark is actively seeking external partnerships to expand and accelerate the growth of its pipeline and portfolio.
For More Latest News Click Here
